News & Events

Happening at Medis

4 Jul 2018 events

See you at the 2018 CPhI Worldwide

Medis is attending the CPhI Worldwide in Madrid later this year. CPhI is the world‘s leading pharmaceutical platform and hosts…

1 Nov 2017 news

Medis wins Company of the Year, EMEA Award

Frankfurt, 24 October 2017: Medis and Generics bulletin are pleased to announce that Medis has won the Company of the…

13 Oct 2017 news

Medis receives two nominations for Global Generics & Biosimilar Awards

Medis receives two nominations for this year’s Global Generics & Biosimilar Awards; as Company of the Year, and Company of…

6 Oct 2017 news

2017 CPhi Worldwide

Medis will be at the CPhI Worldwide in Frankfurt later this month. We look forward to meeting you once again…

3 Aug 2016 news

TEVA COMPLETES AQUISITION OF ACTAVIS GENERICS, INCLUDING MEDIS

Teva has now completed its acquisition of Actavis Generics, which includes Medis. As a result of the acquisition, Medis and…

15 Mar 2016 news

MEDIS ONCE MORE AMONG THE STRONGEST IN ICELAND

Medis was amongst only 682 companies in Iceland to be certified by Creditinfo as The Strongest in Iceland. Creditinfo is…

14 Oct 2015 news

MEDIS WINS BUSINESS DEVELOPMENT OF THE YEAR AWARD

MADRID, 13 October 2015: Medis and Generics bulletin are pleased to announce that Medis has won the Business Development of…

21 Sep 2015 news

MEET US IN MADRID AT THE 2015 CPHI WORLDWIDE

Meet Medis at the 2015 CPhI in Madrid – Hall 9, Stand 9J10. Medis will take its place at the…

15 Sep 2015 news

FOUR MEDIS NOMINATIONS FOR GLOBAL GENERICS & BIOSIMILAR AWARDS

Medis has four nominations for the upcoming 2015 Global Generics & Biosimilar Awards. The awards are set up to recognize…

23 Jun 2015 news

GOLD STANDARD ON EQUAL PAY FOR MEDIS ICELAND

Medis Iceland, along with Actavis Iceland, has been recognized with a Gold Certificate in the recent ‘Equal Pay Audit’ conducted…

6 Feb 2015 news

MEDIS MARKS IMPORTANT MILESTONES – 30/2015

Gearing up for a highly productive year ahead, the team at Medis celebrated an extra dimension to its annual Kick-off…

5 Dec 2014 news

MEDIS GRANTED PREGABALIN MARKETING AUTHORIZATION IN GERMANY IN RECORD TIME

Medis customers granted Pregabalin marketing authorization (MA) in Germany in record time Medis has managed to close the Pregabalin DCP…

2 Dec 2014 news

MEDIS SUCCESSFULLY LAUNCHES CELECOXIB IN GERMANY AND FRANCE AT PATENT EXPIRY

On November 17, Medis successfully launched Celecoxib in Germany and France on Day-1 of patent expiry for its customers. Our…

1 Dec 2014 news

MEDIS ATTENDING CPHI KOREA ON SEPTEMBER 2-3, 2014

Medis will be attending CPhI Korea on September 2-3, 2014. Our Manager of Business Development in the Asia Pacific region,…

5 Nov 2014 news

UPCOMING EVENTS FOR MEDIS IN 2014 – EUROPLX AND PHARMAVENUE

Medis at euroPLX and Pharmavenue in Barcelona in November 2014 Our business development managers will head out to a couple…

11 Sep 2014 news

CPHI 2014 IN PARIS – MEET US THERE

Meet up with us at the CPhI 2014 in Paris! Our people are out in full force in preparing for…

29 Jun 2014 news

TEAM MEDIS COMPLETES THE 2015 WOW CYCLOTHON CHARITY RACE

A group of ten brave Medis employees took part in the 2015 WOW Cyclothon,  a non-stop relay bicycling race around…

8 May 2014 news

UPCOMING EVENTS IN MAY AND JUNE

​Medis regularly attends conferences, business meetings and networking events around the world. We will try to publish the information regularly,…

18 Nov 2013 news

THE MEDIS BOOTH AT CPHI 2013 FRANKFURT A BIG SUCCESS

Hugely Successful CPhI 2013 Frankfurt This year’s CPhI took place in Frankfurt, Germany, from 22-24 of October, 2013. Medis was…

13 Nov 2013 news

MEDIS LAUNCHES TELMISARTAN HCT ON PATENT EXPIRY

Medis launches 37.8 million Telmisartan HCT in 8 European markets Medis launched Telmisartan HCT on patent expiry, 12th December 2013,…

11 Nov 2013 news

UPCOMING EVENTS FOR MEDIS IN 2013

Medis at euroPLX and Pharmavenue in Barcelona Our business development managers will head out to a couple of upcoming pharmaceutical…

26 Jun 2013 news

MEDIS LAUNCHES GENERIC VIAGRA® IN EUROPE AS PATENTS EXPIRE

Medis in cooperation with customer in Italy and Switcherland has now launched Sildenafil tablets on market formation. Sildenafil, the generic…

17 May 2013 news

CUSTOMER COMMUNICATION CENTRALLY MANAGED BY MEDIS SUPPLY CHAIN

Medis is pleased to announce that, following the merger of the third-party businesses of Specifar Pharmaceuticals and Medis, under the…

26 Apr 2013 news

MEDIS TAKES CONTROL OVER BREATH LTD.

Medis is proud to announce that as of last Friday it has taken control over Breath ltd. Breath is a company…

11 Feb 2013 news

AUROBINDO ACQUIRES COMMERCIAL OPERATIONS OF ACTAVIS PLC IN SEVEN COUNTRIES

Valur Ragnarsson, CEO of Medis, recently made the following announcement to our customers regarding the recent deal: On 17 January…

8 Feb 2013 news

MEDIS NUMBER ONE, ONCE AGAIN

Medis has once more topped the list of Outstanding Companies of 2012, just as it did in 2011. Creditinfo conducted an analysis,…

14 Nov 2012 news

RABEPRAZOLE LAUNCH

It is never a dull moment for the Medis launch team, now just 2 weeks after the launch of Riluzole,…

1 Nov 2012 news

MEDIS + SPECIFAR = POWERFUL COMBINATION

Today, November 1, 2012, Watson announced that it had completed the acquisition of the Actavis Group, the parent company of…

30 Oct 2012 news

RILUZOLE LAUNCH

​Following months of preparations, Riluzole was launched on the day of patent expiry, October 23rd, by 22 Medis customers in…

5 Oct 2012 news

MEET MEDIS IN MADRID

The annual CPhI exhibition is upon us yet again. This year it will be held in the Spanish capita, Madrid,…

31 Aug 2012 news

NEW MEDIS OFFICE IN GERMANY

The Medis office in Germany just recently moved offices to a new location at Königsberger Strasse 16, 55218, Ingelheim. The town,…

15 May 2012 news

ATORVASTATIN, THE BIGGEST MEDIS LAUNCH OF THE YEAR

Medis has launched Atorvastatin immediately after the patent expiry this week to 18 customers in Austria, Germany, Denmark, France, the…

25 Apr 2012 news

WATSON TO ACQUIRE ACTAVIS GROUP THE PARENT COMPANY OF MEDIS, FOR EUR 4.25 BILLION

Watson Pharmaceuticals, Inc. (NYSE: WPI) and Actavis Group today jointly announced that Watson has entered into a definitive agreement to…

22 Feb 2012 news

2011 A RECORD LAUNCH YEAR & A HEALTHY OUTLOOK FOR 2012

Last year was a record launch year for Medis with 123 launches within the year. The majority of launches were…

9 Feb 2012 news

MEDIS NUMBER ONE

Medis ehf has been classified as number ONE on the list of Outstanding Companies of 2011. Creditinfo* has conducted an…

8 Dec 2011 news

FIVE NEW DOSSIERS COMPLETED DECEMBER 2011

This month sees the completion by Medis of five new developments: Olmesartan film coated tablets (5mg, 10mg, 20mg, 40mg) Oxycodone…

16 Nov 2011 news

YET ANOTHER SUCCESSFUL LAUNCH ON DAY-1

Medis customers in five major European countries have launched Valsartan and Valsartan HCT tablets immediately after the patents expired. Valsartan…

28 Oct 2011 news

AN EVENING TO REMEMBER

The Medis team at CPhI hosted a reception at Die Schirn Kunsthalle in Frankfurt, Römerberg, Wednesday night. It was an…

25 Oct 2011 news

GUTEN TAG FRANKFURT

​We look forward to meeting you once again at the annual CPhI. This year it’s in Frankfurt, Germany from 25-27…

3 Oct 2011 news

ESOMEPRAZOLE MUPS – DOSSIER COMPLETE

The dossier for Esomeprazole MUPS tablets is now available from Medis and includes both fed and fasted bio studies. Medis…

30 Sep 2011 news

OLANZAPINE – BIGGEST MEDIS LAUNCH FOR 2011

Medis successfully launched Olanzapine in nine European countries toward the end of September, immediately after the expiry of the constraining…

29 Sep 2011 news

SUCCESSFUL PATENT OPPOSITION

Medis / Actavis have won their opposition case on the Fluvastatin SR patent EP948320B1 by Novartis within the Board of…

Locations

worldwide operations and facilities

ACBF5E14-A57C-4383-BDFF-04EA66B1D3D8 Created with sketchtool.